Publications

Access hundreds of peer-reviewed cognitive research papers published by leading neuroscientists using Cogstate technology.

Search

Tag
Author
Journal
Year

Nonvascular retinal imaging markers of preclinical Alzheimer’s disease.

Authors: Alber J, Fernández B, Johnson LN, Lim YY, Maruff P, Santos CY, Snyder PJ

Journal: Alzheimer's & Dementia

Volume & Issue: 4

Page No.: 169-178

Year Published: 2016

INTRODUCTION: In patients with Alzheimer’s disease (AD) and mild cognitive impairment, structural changes in the retina (i.e., reduced thicknesses of the ganglion cell and retinal nerve fiber layers and inclusion bodies that appear to contain beta-amyloid protein [Ab]) have been previously reported. We sought to explore whether anatomic retinal changes are detectable in the preclinical […]

Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer’s disease.

Authors: Lim YY, Maruff P, Noto RB, Ott BR, Salloway S, Santos CY, Schindler R, Snyder PJ, Yoo DC

Journal: Neurobiology of Aging

DOI: 10.1016/j.neurobiolaging.2015.07.009

Year Published: 2015

Disruption in cholinergic neurotransmission is one of the earliest neuropathological changes in preclinical Alzheimer’s disease (AD) and may be associated with abnormal beta-amyloid (Aβ) accumulation. Therefore, disruption of cholinergic neurotransmission with scopolamine may unmask otherwise undetectable cognitive deficits in preclinical AD. To compare the effects of low-dose (0.20 mg s.c.) scopolamine on cognition between Aβ+ […]

Disruption of cholinergic neurotransmission exacerbates Aβ-related cognitive impairment in preclinical Alzheimer’s disease

Authors: Brian R. Ott M.D., Cláudia Y. Santos, Don C. Yoo M.D., Paul Maruff Ph.D., Peter J. Snyder Ph.D., Rachel Schindler Ph.D., Richard B. Noto M.D., Stephen Salloway M.D., Yen Ying Lim Ph.D.

Journal: Neurobiology of Aging

DOI: dx.doi.org/10.1016/j.neurobiolaging.2015.07.009 show

Year Published: 2015

Importance Disruption in cholinergic neurotransmission is one of the earliest neuropathological changes in preclinical Alzheimer’s disease (AD), and may be associated with abnormal beta-amyloid (Aβ) accumulation. Therefore, disruption of cholinergic neurotransmission with scopolamine may unmask otherwise undetectable cognitive deficits in preclinical AD. Objective To compare the effects of low-dose (0.20mg s.c.) scopolamine on cognition between […]

Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study.

Authors: Ames D, Bush AI, Ellis KA, Faux N, Flicker L, Foster J, Hilmer S, Lautenschlager NT, Martins RN, Maruff P, Masters CL, Rowe C, Sittironnarit G, Szoeke C

Journal: Dementia and Geriatric Cognitive Disorders

Volume & Issue: 31 & 3

Page No.: 173-8

DOI: 10.1159/000325171

Year Published: 2011

BACKGROUND/AIMS: The nature and extent of adverse cognitive effects due to the prescription of anticholinergic drugs in older people with and without dementia is unclear. METHODS: We calculated the anticholinergic load (ACL) of medications taken by participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing, a cohort of 211 Alzheimer’s disease (AD) […]